236 related articles for article (PubMed ID: 35817480)
1. TransCon IL-2 β/γ: a novel long-acting prodrug with sustained release of an IL-2Rβ/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen DB; Kvarnhammar AM; Laufer B; Knappe T; Karlsson JJ; Hong E; Lee YC; Thakar D; Zúñiga LA; Bang K; Sabharwal SS; Uppal K; Olling JD; Kjaergaard K; Kurpiers T; Schnabel M; Reich D; Glock P; Zettler J; Krusch M; Bernhard A; Heinig S; Konjik V; Wegge T; Hehn Y; Killian S; Viet L; Runz J; Faltinger F; Tabrizi M; Abel KL; Breinholt VM; Singel SM; Sprogøe K; Punnonen J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35817480
[TBL] [Abstract][Full Text] [Related]
2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
3. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamic Effects of Nemvaleukin Alfa, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, in Cynomolgus Monkeys.
Lopes JE; Sun L; Flick HL; Murphy EA; Losey HC
J Pharmacol Exp Ther; 2021 Nov; 379(2):203-210. PubMed ID: 34362793
[TBL] [Abstract][Full Text] [Related]
5. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral delivery of TransCon
Zúñiga LA; Leßmann T; Uppal K; Bisek N; Hong E; Rasmussen CE; Karlsson JJ; Zettler J; Holten-Andersen L; Bang K; Thakar D; Lee YC; Martinez S; Sabharwal SS; Stark S; Faltinger F; Kracker O; Weisbrod S; Müller R; Voigt T; Bigott K; Tabrizifard M; Breinholt VM; Mirza AM; Rosen DB; Sprogøe K; Punnonen J
Cancer Cell Int; 2022 Sep; 22(1):286. PubMed ID: 36123697
[TBL] [Abstract][Full Text] [Related]
7. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
8. Surface and intracellular interleukin-2 receptor expression on various resting and activated populations involved in cell-mediated immunity in human peripheral blood.
Hodge S; Hodge G; Flower R; Han P
Scand J Immunol; 2000 Jan; 51(1):67-72. PubMed ID: 10632978
[TBL] [Abstract][Full Text] [Related]
9. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M; Hoen M; Darragh LB; Knitz MW; Nguyen D; Gadwa J; Durini G; Karakoc I; Grier A; Neupert B; Van Court B; Abdelazeem KNM; Yu J; Olimpo NA; Corbo S; Ross RB; Pham TT; Joshi M; Kedl RM; Saviola AJ; Amann M; Umaña P; Codarri Deak L; Klein C; D'Alessandro A; Karam SD
Cancer Cell; 2023 May; 41(5):950-969.e6. PubMed ID: 37116489
[TBL] [Abstract][Full Text] [Related]
11. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
12. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy.
Charych D; Khalili S; Dixit V; Kirk P; Chang T; Langowski J; Rubas W; Doberstein SK; Eldon M; Hoch U; Zalevsky J
PLoS One; 2017; 12(7):e0179431. PubMed ID: 28678791
[TBL] [Abstract][Full Text] [Related]
13. Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
Holten-Andersen L; Pihl S; Rasmussen CE; Zettler J; Maitro G; Baron J; Heinig S; Hoffmann E; Wegge T; Krusch M; Faltinger F; Killian S; Sprogoe K; Karpf DB; Breinholt VM; Cleemann F
J Bone Miner Res; 2019 Nov; 34(11):2075-2086. PubMed ID: 31291476
[TBL] [Abstract][Full Text] [Related]
14. IL-2 responsiveness of CD4 and CD8 lymphocytes: further investigations with human IL-2Rbeta transgenic mice.
Gesbert F; Moreau JL; Thèze J
Int Immunol; 2005 Aug; 17(8):1093-102. PubMed ID: 16037071
[TBL] [Abstract][Full Text] [Related]
15. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
16. IL-2K35C-moFA, a Long-Acting Engineered Cytokine with Decreased Interleukin 2 Receptor α Binding, Improved the Cellular Selectivity Profile and Antitumor Efficacy in a Mouse Tumor Model.
Wang X; Chen G; Nie L; Wu Z; Wang X; Pan C; Chen X; Zhao X; Zhu J; He Q; Wang H
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230665
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
18. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models.
Charych DH; Hoch U; Langowski JL; Lee SR; Addepalli MK; Kirk PB; Sheng D; Liu X; Sims PW; VanderVeen LA; Ali CF; Chang TK; Konakova M; Pena RL; Kanhere RS; Kirksey YM; Ji C; Wang Y; Huang J; Sweeney TD; Kantak SS; Doberstein SK
Clin Cancer Res; 2016 Feb; 22(3):680-90. PubMed ID: 26832745
[TBL] [Abstract][Full Text] [Related]
19. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
[TBL] [Abstract][Full Text] [Related]
20. Cutting Edge: Differential Fine-Tuning of IL-2- and IL-15-Dependent Functions by Targeting Their Common IL-2/15Rβ/γc Receptor.
Meghnem D; Morisseau S; Frutoso M; Trillet K; Maillasson M; Barbieux I; Khaddage S; Leray I; Hildinger M; Quéméner A; Jacques Y; Mortier E
J Immunol; 2017 Jun; 198(12):4563-4568. PubMed ID: 28507024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
